La Jolla Pharmaceutical Co
F:LJPP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (3.5), the stock would be worth €5.61 (8% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.8 | €6.07 |
0%
|
| 3-Year Average | 3.5 | €5.61 |
-8%
|
| 5-Year Average | 3.5 | €5.53 |
-9%
|
| Industry Average | 6.7 | €10.65 |
+75%
|
| Country Average | 2.4 | €3.85 |
-37%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
€151.5m
|
/ |
Jul 2022
$46.5m
|
= |
|
|
€151.5m
|
/ |
Dec 2022
$56.1m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
L
|
La Jolla Pharmaceutical Co
F:LJPP
|
151.5m EUR | 3.8 | 45 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | 5.8 | 85.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 5 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD | 5.5 | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 9 | 27.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD | 5.1 | 16.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 11.3 | 36.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 2.7 | 29.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
La Jolla Pharmaceutical Co
Glance View
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
